9 Meters Biopharma
9 Meters Biopharma, Inc. is a clinical-stage biotechnology company that focuses on patients with rare disorders and unmet medical needs. Drug candidates for short bowel syndrome (SBS) and celiac disease are in the company's pipeline.
It is working on NM-002, a long-acting injectable GLP-1 agonist in Phase 2 clinical trials for SBS, as well as Larazotide, a celiac disease Phase 3 therapeutic in development.
NM-003, a proprietary long-acting GLP-2 agonist, and NM-004, a double-cleaved mesalamine with an immunomodulator, are also under development for rare and/or orphan indications. The headquarters of 9 Meters Biopharma, Inc. are in Raleigh, North Carolina.
- NASDAQ: NMTR
- Stock Price: $0.84 (+$0.08)
- Market Cap: $113.50 million
- Consensus Rating: Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
- Consensus Price Target: $5.00 (498.8% Upside)
Website: 9meters.com
Market Cap: 177.689M
